Bruno Vigneron Photographer

  • Galleries
    • All Galleries
    • Search
    • Cart
    • Lightbox
    • Client Area
  • Home
  • Blog
  • Port-Folio
  • Contact
  • Instagram
  • About
  • Prints
  • Facebook
  • Twitter
x

Search Results

Refine Search
Match all words
Match any word
Prints
Personal Use
Royalty-Free
Rights-Managed
(leave unchecked to
search all images)
36 images found
twitterlinkedinfacebook

Loading ()...

  • Preparation of ET-D5.<br />
<br />
ET-D5 is an anti-cancer molecule that can kill cancer tumors without damaging nearby organs.<br />
ET-D5 is developed by the start-up Ecrins -Therapeutics, founded in 2010.<br />
Oral chemotherapy.<br />
Aurélie Juhem, scientist and research director at Ecrins Therapeutics, is working on this molecule cancer for seven long years in partnership with the Institut Curie.<br />
Many promising tests have already been carried out on mouses.<br />
To move to the next stage, clinical trials in humans, the young start-up must raise € 500,000.<br />
The Financement of this research  will be done through a platform of "crowdfunding".<br />
When this amount will be found, the first human trials could begin on patients of cancer center Léon Bérard in Lyon.
    ET-D5_028.jpg
  • ET-D5 is an anti-cancer molecule that can kill cancer tumors without damaging nearby organs.<br />
ET-D5 is developed by the start-up Ecrins -Therapeutics, founded in 2010.<br />
Oral chemotherapy.<br />
Aurélie Juhem, scientist and research director at Ecrins Therapeutics, is working on this molecule cancer for seven long years in partnership with the Institut Curie.<br />
Many promising tests have already been carried out on mouses.<br />
To move to the next stage, clinical trials in humans, the young start-up must raise € 500,000.<br />
The Financement of this research  will be done through a platform of "crowdfunding".<br />
When this amount will be found, the first human trials could begin on patients of cancer center Léon Bérard in Lyon.
    ET-D5_007.jpg
  • The compound ET-D5<br />
<br />
ET-D5 is an anti-cancer molecule that can kill cancer tumors without damaging nearby organs.<br />
ET-D5 is developed by the start-up Ecrins -Therapeutics, founded in 2010.<br />
Oral chemotherapy.<br />
Aurélie Juhem, scientist and research director at Ecrins Therapeutics, is working on this molecule cancer for seven long years in partnership with the Institut Curie.<br />
Many promising tests have already been carried out on mouses.<br />
To move to the next stage, clinical trials in humans, the young start-up must raise € 500,000.<br />
The Financement of this research  will be done through a platform of "crowdfunding".<br />
When this amount will be found, the first human trials could begin on patients of cancer center Léon Bérard in Lyon.
    ET-D5_029.jpg
  • ET-D5 is an anti-cancer molecule that can kill cancer tumors without damaging nearby organs.<br />
ET-D5 is developed by the start-up Ecrins -Therapeutics, founded in 2010.<br />
Oral chemotherapy.<br />
Aurélie Juhem, scientist and research director at Ecrins Therapeutics, is working on this molecule cancer for seven long years in partnership with the Institut Curie.<br />
Many promising tests have already been carried out on mouses.<br />
To move to the next stage, clinical trials in humans, the young start-up must raise € 500,000.<br />
The Financement of this research  will be done through a platform of "crowdfunding".<br />
When this amount will be found, the first human trials could begin on patients of cancer center Léon Bérard in Lyon.
    ET-D5_016.jpg
  • Preparation of ET-D5.<br />
<br />
ET-D5 is an anti-cancer molecule that can kill cancer tumors without damaging nearby organs.<br />
ET-D5 is developed by the start-up Ecrins -Therapeutics, founded in 2010.<br />
Oral chemotherapy.<br />
Aurélie Juhem, scientist and research director at Ecrins Therapeutics, is working on this molecule cancer for seven long years in partnership with the Institut Curie.<br />
Many promising tests have already been carried out on mouses.<br />
To move to the next stage, clinical trials in humans, the young start-up must raise € 500,000.<br />
The Financement of this research  will be done through a platform of "crowdfunding".<br />
When this amount will be found, the first human trials could begin on patients of cancer center Léon Bérard in Lyon.
    ET-D5_027.jpg
  • ET-D5 is an anti-cancer molecule that can kill cancer tumors without damaging nearby organs.<br />
ET-D5 is developed by the start-up Ecrins -Therapeutics, founded in 2010.<br />
Oral chemotherapy.<br />
Aurélie Juhem, scientist and research director at Ecrins Therapeutics, is working on this molecule cancer for seven long years in partnership with the Institut Curie.<br />
Many promising tests have already been carried out on mouses.<br />
To move to the next stage, clinical trials in humans, the young start-up must raise € 500,000.<br />
The Financement of this research  will be done through a platform of "crowdfunding".<br />
When this amount will be found, the first human trials could begin on patients of cancer center Léon Bérard in Lyon.
    ET-D5_015.jpg
  • Preparation of ET-D5.<br />
<br />
ET-D5 is an anti-cancer molecule that can kill cancer tumors without damaging nearby organs.<br />
ET-D5 is developed by the start-up Ecrins -Therapeutics, founded in 2010.<br />
Oral chemotherapy.<br />
Aurélie Juhem, scientist and research director at Ecrins Therapeutics, is working on this molecule cancer for seven long years in partnership with the Institut Curie.<br />
Many promising tests have already been carried out on mouses.<br />
To move to the next stage, clinical trials in humans, the young start-up must raise € 500,000.<br />
The Financement of this research  will be done through a platform of "crowdfunding".<br />
When this amount will be found, the first human trials could begin on patients of cancer center Léon Bérard in Lyon.
    ET-D5_026.jpg
  • The sales manager of Ecrins Therapeutics, Dr Axel Defays.<br />
<br />
Dr Axel Defays: Axel Defays graduated from Aix-Marseille University in 2010, with a PhD degree in Immunology. After a few years of work outside the academic research field, he made a career change to sales management by entering a Master program in 2014. Looking for an opportunity to help a young biotechnology company in its development, he joined Ecrins Therapeutics as a sales manager in early 2015. He is now dedicated to bring Ecrins Therapeutics’ reputation of scientific excellence to the international stage.
    ET-D5_031.jpg
  • The compound ET-D5.
    ET-D5_017.jpg
  • Dr Delphine Lecerclé is preparing ET-D5<br />
<br />
Dr Delphine LECERCLE graduated from Paris-Sud University in 2007, with a PhD degree in organic chemistry. After a postdoctoral training at Paris Descartes University, she joined Ecrins Therapeutics in 2011 as responsible of the medicinal chemistry
    ET-D5_023.jpg
  • The sales manager of Ecrins Therapeutics, Dr Axel Defays.<br />
<br />
Dr Axel Defays: Axel Defays graduated from Aix-Marseille University in 2010, with a PhD degree in Immunology. After a few years of work outside the academic research field, he made a career change to sales management by entering a Master program in 2014. Looking for an opportunity to help a young biotechnology company in its development, he joined Ecrins Therapeutics as a sales manager in early 2015. He is now dedicated to bring Ecrins Therapeutics’ reputation of scientific excellence to the international stage.
    ET-D5_030.jpg
  • Dr Delphine Lecerclé is preparing ET-D5<br />
<br />
Dr Delphine LECERCLE graduated from Paris-Sud University in 2007, with a PhD degree in organic chemistry. After a postdoctoral training at Paris Descartes University, she joined Ecrins Therapeutics in 2011 as responsible of the medicinal chemistry
    ET-D5_025.jpg
  • Dr Aurélie Juhem and Dr Andrei Popov are analyzing fluorescence microscopy images.<br />
<br />
Dr Aurélie JUHEM met Dr Andrei Popov in 2005 to start her PhD training in his research team. They develop an innovative screening strategy to identify new anti-proliferative drugs targeting cell divison from a chemical library provided by the Institut Curie. They identified further new bioactive chemical entities including an ET-D5 structural analogue. Graduated in 2008 from Joseph Fourier University (Grenoble), she continued ET-D5 research program as a postdoctoral researcher with Dr Popov. This work was patented in 2010 and Ecrins therapeutics was founded to develop ET-D5 under preclinical studies.<br />
Since 2010, Dr Aurelie Juhem is the R&D Director of Ecrins Therapeutics.
    ET-D5_010.jpg
  • Dr Aurélie Juhem is observing cancer cells incubated with ET-D5 using fluorescence microscopy<br />
<br />
Dr Aurélie JUHEM met Dr Andrei Popov in 2005 to start her PhD training in his research team. They develop an innovative screening strategy to identify new anti-proliferative drugs targeting cell divison from a chemical library provided by the Institut Curie. They identified further new bioactive chemical entities including an ET-D5 structural analogue. Graduated in 2008 from Joseph Fourier University (Grenoble), she continued ET-D5 research program as a postdoctoral researcher with Dr Popov. This work was patented in 2010 and Ecrins therapeutics was founded to develop ET-D5 under preclinical studies.<br />
Since 2010, Dr Aurelie Juhem is the R&D Director of Ecrins Therapeutics.
    ET-D5_009.jpg
  • Dr Aurélie Juhem is working under laminar hood which provides a sterile environment for the cell culture experiments.<br />
<br />
Dr Aurélie JUHEM met Dr Andrei Popov in 2005 to start her PhD training in his research team. They develop an innovative screening strategy to identify new anti-proliferative drugs targeting cell divison from a chemical library provided by the Institut Curie. They identified further new bioactive chemical entities including an ET-D5 structural analogue. Graduated in 2008 from Joseph Fourier University (Grenoble), she continued ET-D5 research program as a postdoctoral researcher with Dr Popov. This work was patented in 2010 and Ecrins therapeutics was founded to develop ET-D5 under preclinical studies.<br />
Since 2010, Dr Aurelie Juhem is the R&D Director of Ecrins Therapeutics.
    ET-D5_002.jpg
  • Dr Andrei POPOV, dirigeant d’Ecrins Therapeutics<br />
<br />
Trained initially as a doctor, Andrei Popov graduated from the Sechenov Moscow Medical Academy in 1988. He then worked as doctoral and postdoctoral fellow at the Babraham Insitute in Cambridge, UK, and at the European Molecular Biology Laboratory (EMBL), Heidelberg, Germany. He received his PhD in biology in 1997 for his work on the creation of transgenic mice carrying and expressing functional germ-line shaped human immunoglobulin loci. A European Molecular Biology Organization (EMBO) and Human Frontier Science Program (HFSP) fellow during his spell at EMBL, in 2003 Andrei Popov became a laureate of the Inserm program “Avenir”. This grant allowed him to establish an independent research group at Inserm in Grenoble, France, with a focus on the mechanisms of cell division and bioactive small molecules, both fields relevant to oncology. Andrei authored 25 publications in peer-reviewed scientific journals, obtained 10 research grants and is the named inventor on 2 patents. <br />
In 2010 Andrei left academia in order to create (with Dr Aurelie JUHEM and Pr François Berger) the startup Ecrins Therapeutics.
    ET-D5_034.jpg
  • Dr Andrei POPOV, dirigeant d’Ecrins Therapeutics<br />
<br />
Trained initially as a doctor, Andrei Popov graduated from the Sechenov Moscow Medical Academy in 1988. He then worked as doctoral and postdoctoral fellow at the Babraham Insitute in Cambridge, UK, and at the European Molecular Biology Laboratory (EMBL), Heidelberg, Germany. He received his PhD in biology in 1997 for his work on the creation of transgenic mice carrying and expressing functional germ-line shaped human immunoglobulin loci. A European Molecular Biology Organization (EMBO) and Human Frontier Science Program (HFSP) fellow during his spell at EMBL, in 2003 Andrei Popov became a laureate of the Inserm program “Avenir”. This grant allowed him to establish an independent research group at Inserm in Grenoble, France, with a focus on the mechanisms of cell division and bioactive small molecules, both fields relevant to oncology. Andrei authored 25 publications in peer-reviewed scientific journals, obtained 10 research grants and is the named inventor on 2 patents. <br />
In 2010 Andrei left academia in order to create (with Dr Aurelie JUHEM and Pr François Berger) the startup Ecrins Therapeutics.
    ET-D5_033.jpg
  • Ecrins Therapeutics team.
    ET-D5_035.jpg
  • The sales manager of Ecrins Therapeutics, Dr Axel Defays.<br />
<br />
Dr Axel Defays: Axel Defays graduated from Aix-Marseille University in 2010, with a PhD degree in Immunology. After a few years of work outside the academic research field, he made a career change to sales management by entering a Master program in 2014. Looking for an opportunity to help a young biotechnology company in its development, he joined Ecrins Therapeutics as a sales manager in early 2015. He is now dedicated to bring Ecrins Therapeutics’ reputation of scientific excellence to the international stage.
    ET-D5_032.jpg
  • Dr Delphine Lecerclé is preparing ET-D5<br />
<br />
Dr Delphine LECERCLE graduated from Paris-Sud University in 2007, with a PhD degree in organic chemistry. After a postdoctoral training at Paris Descartes University, she joined Ecrins Therapeutics in 2011 as responsible of the medicinal chemistry
    ET-D5_022.jpg
  • Dr Aurélie Juhem is preparing protein samples for bioassays.<br />
<br />
Dr Aurélie JUHEM met Dr Andrei Popov in 2005 to start her PhD training in his research team. They develop an innovative screening strategy to identify new anti-proliferative drugs targeting cell divison from a chemical library provided by the Institut Curie. They identified further new bioactive chemical entities including an ET-D5 structural analogue. Graduated in 2008 from Joseph Fourier University (Grenoble), she continued ET-D5 research program as a postdoctoral researcher with Dr Popov. This work was patented in 2010 and Ecrins therapeutics was founded to develop ET-D5 under preclinical studies.<br />
Since 2010, Dr Aurelie Juhem is the R&D Director of Ecrins Therapeutics.
    ET-D5_006.jpg
  • Dr Aurélie Juhem and Dr Andrei Popov are analyzing fluorescence microscopy images.<br />
<br />
Dr Aurélie JUHEM met Dr Andrei Popov in 2005 to start her PhD training in his research team. They develop an innovative screening strategy to identify new anti-proliferative drugs targeting cell divison from a chemical library provided by the Institut Curie. They identified further new bioactive chemical entities including an ET-D5 structural analogue. Graduated in 2008 from Joseph Fourier University (Grenoble), she continued ET-D5 research program as a postdoctoral researcher with Dr Popov. This work was patented in 2010 and Ecrins therapeutics was founded to develop ET-D5 under preclinical studies.<br />
Since 2010, Dr Aurelie Juhem is the R&D Director of Ecrins Therapeutics.
    ET-D5_012.jpg
  • Dr Aurélie Juhem and Dr Andrei Popov are analyzing fluorescence microscopy images.<br />
<br />
Dr Aurélie JUHEM met Dr Andrei Popov in 2005 to start her PhD training in his research team. They develop an innovative screening strategy to identify new anti-proliferative drugs targeting cell divison from a chemical library provided by the Institut Curie. They identified further new bioactive chemical entities including an ET-D5 structural analogue. Graduated in 2008 from Joseph Fourier University (Grenoble), she continued ET-D5 research program as a postdoctoral researcher with Dr Popov. This work was patented in 2010 and Ecrins therapeutics was founded to develop ET-D5 under preclinical studies.<br />
Since 2010, Dr Aurelie Juhem is the R&D Director of Ecrins Therapeutics.
    ET-D5_011.jpg
  • Ecrins Therapeutics team.
    ET-D5_036.jpg
  • Dr Delphine Lecerclé is observing ET-D5.<br />
Dr Delphine LECERCLE graduated from Paris-Sud University in 2007, with a PhD degree in organic chemistry. After a postdoctoral training at Paris Descartes University, she joined Ecrins Therapeutics in 2011 as responsible of the medicinal chemistry
    ET-D5_019.jpg
  • Dr Aurélie Juhem and Dr Andrei Popov are analyzing fluorescence microscopy images.<br />
<br />
Dr Aurélie JUHEM met Dr Andrei Popov in 2005 to start her PhD training in his research team. They develop an innovative screening strategy to identify new anti-proliferative drugs targeting cell divison from a chemical library provided by the Institut Curie. They identified further new bioactive chemical entities including an ET-D5 structural analogue. Graduated in 2008 from Joseph Fourier University (Grenoble), she continued ET-D5 research program as a postdoctoral researcher with Dr Popov. This work was patented in 2010 and Ecrins therapeutics was founded to develop ET-D5 under preclinical studies.<br />
Since 2010, Dr Aurelie Juhem is the R&D Director of Ecrins Therapeutics.
    ET-D5_013.jpg
  • Dr Aurélie Juhem is preparing protein samples for bioassays.<br />
<br />
Dr Aurélie JUHEM met Dr Andrei Popov in 2005 to start her PhD training in his research team. They develop an innovative screening strategy to identify new anti-proliferative drugs targeting cell divison from a chemical library provided by the Institut Curie. They identified further new bioactive chemical entities including an ET-D5 structural analogue. Graduated in 2008 from Joseph Fourier University (Grenoble), she continued ET-D5 research program as a postdoctoral researcher with Dr Popov. This work was patented in 2010 and Ecrins therapeutics was founded to develop ET-D5 under preclinical studies.<br />
Since 2010, Dr Aurelie Juhem is the R&D Director of Ecrins Therapeutics.
    ET-D5_005.jpg
  • Protein sample prepared in Laemmli buffer.
    ET-D5_004.jpg
  • Dr Aurélie Juhem is puting human cancer cells in a CO2 incubator used to maintain optimal conditions for cell growth.<br />
<br />
Dr Aurélie JUHEM met Dr Andrei Popov in 2005 to start her PhD training in his research team. They develop an innovative screening strategy to identify new anti-proliferative drugs targeting cell divison from a chemical library provided by the Institut Curie. They identified further new bioactive chemical entities including an ET-D5 structural analogue. Graduated in 2008 from Joseph Fourier University (Grenoble), she continued ET-D5 research program as a postdoctoral researcher with Dr Popov. This work was patented in 2010 and Ecrins therapeutics was founded to develop ET-D5 under preclinical studies.<br />
Since 2010, Dr Aurelie Juhem is the R&D Director of Ecrins Therapeutics.
    ET-D5_003.jpg
  • Dr Aurélie Juhem is working under laminar hood which provides a sterile environment for the cell culture experiments.<br />
<br />
Dr Aurélie JUHEM met Dr Andrei Popov in 2005 to start her PhD training in his research team. They develop an innovative screening strategy to identify new anti-proliferative drugs targeting cell divison from a chemical library provided by the Institut Curie. They identified further new bioactive chemical entities including an ET-D5 structural analogue. Graduated in 2008 from Joseph Fourier University (Grenoble), she continued ET-D5 research program as a postdoctoral researcher with Dr Popov. This work was patented in 2010 and Ecrins therapeutics was founded to develop ET-D5 under preclinical studies.<br />
Since 2010, Dr Aurelie Juhem is the R&D Director of Ecrins Therapeutics.
    ET-D5_001.jpg
  • Dr Delphine Lecerclé is preparing ET-D5<br />
<br />
Dr Delphine LECERCLE graduated from Paris-Sud University in 2007, with a PhD degree in organic chemistry. After a postdoctoral training at Paris Descartes University, she joined Ecrins Therapeutics in 2011 as responsible of the medicinal chemistry
    ET-D5_024.jpg
  • Dr Aurélie Juhem is observing cancer cells incubated with ET-D5 using fluorescence microscopy<br />
<br />
Dr Aurélie JUHEM met Dr Andrei Popov in 2005 to start her PhD training in his research team. They develop an innovative screening strategy to identify new anti-proliferative drugs targeting cell divison from a chemical library provided by the Institut Curie. They identified further new bioactive chemical entities including an ET-D5 structural analogue. Graduated in 2008 from Joseph Fourier University (Grenoble), she continued ET-D5 research program as a postdoctoral researcher with Dr Popov. This work was patented in 2010 and Ecrins therapeutics was founded to develop ET-D5 under preclinical studies.<br />
Since 2010, Dr Aurelie Juhem is the R&D Director of Ecrins Therapeutics.
    ET-D5_008.jpg
  • Dr Delphine Lecerclé is observing ET-D5.<br />
Dr Delphine LECERCLE graduated from Paris-Sud University in 2007, with a PhD degree in organic chemistry. After a postdoctoral training at Paris Descartes University, she joined Ecrins Therapeutics in 2011 as responsible of the medicinal chemistry
    ET-D5_020.jpg
  • Dr Delphine Lecerclé is observing ET-D5.<br />
Dr Delphine LECERCLE graduated from Paris-Sud University in 2007, with a PhD degree in organic chemistry. After a postdoctoral training at Paris Descartes University, she joined Ecrins Therapeutics in 2011 as responsible of the medicinal chemistry
    ET-D5_018.jpg
  • Dr Aurélie Juhem and Dr Andrei Popov are analyzing fluorescence microscopy images.<br />
<br />
Dr Aurélie JUHEM met Dr Andrei Popov in 2005 to start her PhD training in his research team. They develop an innovative screening strategy to identify new anti-proliferative drugs targeting cell divison from a chemical library provided by the Institut Curie. They identified further new bioactive chemical entities including an ET-D5 structural analogue. Graduated in 2008 from Joseph Fourier University (Grenoble), she continued ET-D5 research program as a postdoctoral researcher with Dr Popov. This work was patented in 2010 and Ecrins therapeutics was founded to develop ET-D5 under preclinical studies.<br />
Since 2010, Dr Aurelie Juhem is the R&D Director of Ecrins Therapeutics.
    ET-D5_014.jpg
  • Dr Delphine Lecerclé is observing ET-D5.<br />
Dr Delphine LECERCLE graduated from Paris-Sud University in 2007, with a PhD degree in organic chemistry. After a postdoctoral training at Paris Descartes University, she joined Ecrins Therapeutics in 2011 as responsible of the medicinal chemistry
    ET-D5_021.jpg